In Brief: DynaGen
This article was originally published in The Gray Sheet
Executive Summary
DynaGen: Licenses breast biopsy technology from privately held BioLoc, Inc. that is intended to "overcome the shortcomings of the core needle biopsy procedure by accurately guiding the surgical biopsy instruments directly to the suspected tissue lesion identified during mammography examination." The technology will "allow us to enter the $1 bil. breast biopsy market with a differentiated product that will be an improvement over current procedures," DynaGen says, and will provide opportunities for "future innovative product offerings in cancer screening and diagnosis"...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.